CLAIMS

1. Use of a protein having IgG cysteine protease activity or IgG endoglycosidase activity in the manufacture of a medicament for improving the benefit to a subject of a therapy, in which:

(a) the protein is to be administered to the subject; and subsequently

(b) the therapy is to be administered to the subject; and in which:

the therapy is an organ transplant;

the amount of the protein administered is sufficient to eliminate Fc receptor binding by substantially all IgG molecules present in the serum of the subject; and

the administration of the protein and the administration of the organ transplant are to be separated by a time interval which is at most 24 hours.

2. Use according to Claim 1, in which:

(i) The protein having IgG cysteine protease activity is an IgG cyteine protease from a Streptococcus bacterium such as Streptococcus pyogenes, optionally in which the protein is IdeS or MAC2; or

(ii) The protein having IgG endoglycosidase activity is an IgG endoglycosidase from a Streptococcus bacterium, such as Streptococcus pyogenes, Streptococcus equi or Streptococcus zooepidemicus, or from Corynebacterium pseudotuberculosis, Enterococcus faecalis, or Elizabethkingia meningoseptica, optionally in which the protein is EndoS, CP40, EndoE, or $EndoF_2$.

3. Use according to Claim 1, in which

(i) The protein having IgG cysteine protease activity is a protein which comprises or consists of the amino acid sequence of SEQ ID NO: 1, or a fragment or variant thereof which has IgG cysteine protease activity; or

(ii) The protein having IgG endoglycosidase activity is a protein which comprises or consists of the amino acid sequence of SEQ ID NO: 2, or a fragment or variant thereof which has IgG endoglycosidase activity.

4. Use according to any preceding claim, in which the protein is to be administered by intravenous infusion and/or the amount of the protein that is to be administered is between 0.01mg/kg BW and 2mg/kg BW, between 0.04 and 2mg/kg BW, between 0.12mg/kg BW and

2mg/kg BW, between 0.24mg/kg BW and 2mg/kg BW, or between 1mg/kg BW and 2mg/kg BW.

5. Use according to any preceding claim in which:

the lower limit of the time interval is selected from: at least 30 minutes, at least 1 hour, at least 2 hours, at least 3 hours, at least 4 hours, at least 5 hours, or at least 6 hours; and

the upper limit of the time interval is independently selected from: at most 10 hours, at most 8 hours, at most 7 hours or at most 6 hours.

6. Use according to any preceding claim, in which the time interval is of 30 minutes to 1 hour, 30 minutes to 2 hours, 30 minutes to 3 hours, 30 minutes to 4 hours, 30 minutes to 5 hours, 30 minutes to 6 hours, 1 to 2 hours, 1 to 3 hours, 1 to 4 hours, 1 to 5 hours, 1 to 6 hours, 2 to 3 hours, 2 to 4 hours, 2 to 5 hours, 2 to 6 hours, 3 to 4 hours, 3 to 5 hours, 3 to 6 hours, 4 to 5 hours, 4 to 6 hours, or 5 to 6 hours.

7. Use according to any of Claims 1 to 6, in which the organ transplant is a kidney, liver, heart, pancreas, lung, or small intestine transplant.

8. Use according to Claim 7, in which at the same time or immediately prior to transplantation, induction suppression of T cells and/or B cells is to be conducted in the patient.

9. Use according to Claim 8, in which the induction suppression means that an effective amount of at least one of Muromonab, Basiliximab, Daclizumab, an antithymocyte globulin (ATG) antibody, a lymphocyte immune globulin, anti-thymocyte globulin preparation (ATGAM), or Rituximab is to be administered to the patient.